Yuan, S., Jiang, F., Chen, J., Lebwohl, B., Green, P. H. R., Leffler, D., Larsson, S. C., Li, X., & Ludvigsson, J. F. (2024). Phenome-wide Mendelian randomization analysis reveals multiple health comorbidities of coeliac disease. EBioMedicine, 101, 105033. https://doi.org/10.1016/j.ebiom.2024.105033

GORDON, E. R., ADEUYAN, O., SCHREIDAH, C. M., CHEN, C., TRAGER, M. H., LAPOLLA, B. A., FAHMY, L. M., WENG, C., & GESKIN, L. J. (2023). Clusters, crop dusters, and myth busters: a scoping review of environmental exposures and cutaneous T-cell lymphoma. Italian Journal of Dermatology and Venereology, 158(6). https://doi.org/10.23736/s2784-8671.23.07729-0

Olén, O., Smedby, K. E., Erichsen, R., Pedersen, L., Halfvarson, J., Hallqvist-Everhov, Å., Bryder, N., Askling, J., Ekbom, A., Sachs, M. C., Sørensen, H. T., Ludvigsson, J. F., Olsson, M., Myrelid, P., Hjortswang, H., Bengtsson, J., Strid, H., Andersson, M., Jäghult, S., … Karling, P. (2023). Increasing Risk of Lymphoma Over Time in Crohn’s Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study. Clinical Gastroenterology and Hepatology, 21(12), 3132–3142. https://doi.org/10.1016/j.cgh.2023.04.001

Afify, Z. A. M., Taj, M. M., Orjuela‐Grimm, M., Srivatsa, K., Miller, T. P., Edington, H. J., Dalal, M., Robles, J., Ford, J. B., Ehrhardt, M. J., Ureda, T. J., Rubinstein, J. D., McCormack, S., Rivers, J. M., Chisholm, K. M., Kavanaugh, M. K., Bukowinski, A. J., Friehling, E. D., Ford, M. C., … Mason, C. C. (2022). Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780–789. Portico. https://doi.org/10.1002/cncr.34600

Ricard, F., Barrington, S., Korn, R., Brueggenwerth, G., Trotman, J., Cheson, B., Salles, G., Schwartz, L., Goldmacher, G., Jarecha, R., Narang, J., Broussais, F., Galette, P., Liu, M., Bajpai, S., Perlman, E., Gillis, J., Smalberg, I., Terve, P., … Schmid, A. (2022). Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical). Journal of Nuclear Medicine, 64(2), 239–243. https://doi.org/10.2967/jnumed.122.264124

Ricard, F., Cheson, B., Barrington, S., Trotman, J., Schmid, A., Brueggenwerth, G., Salles, G., Schwartz, L., Goldmacher, G., Jarecha, R., Narang, J., Broussais, F., Galette, P., Liu, M., Bajpai, S., Perlman, E., Gillis, J., Smalberg, I., Terve, P., … Korn, R. (2022). Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical). Journal of Nuclear Medicine, 64(1), 102–108. https://doi.org/10.2967/jnumed.122.264106

Ryu, Y. K., & Amengual, J. E. (2022). Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. The Lancet Haematology, 9(7), e463–e465. https://doi.org/10.1016/s2352-3026(22)00169-7